FindTrial
Sign In

A single arm preliminary study for evaluating the safety & efficiency of CD19 chimeric antigen receptor T cells (CAR-T) in the treatment of the CD19-positive patients with chemotherapy-tolerant or relapsed B cell Lymphoma or Leukemia

A single arm preliminary study for evaluating the safety & efficiency of CD19 chimeric antigen receptor T cells (CAR-T) in the treatment of the CD19-positive patients with chemotherapy-tolerant or relapsed B cell Lymphoma or Leukemia

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026329
Enrollment
Unknown
Registered
2019-09-30
Start date
2018-10-24
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD19-positive patients with chemotherapy-tolerant or relapsed B cell Lymphoma or Leukemia

Interventions

Case series:CD19 Specificity CART Cell Therapy

Sponsors

Hematology Department, Xi'an High-tech Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years old, male or female; 2. Have a CD19+ B cell malignancy and no other effective treatment options (eg, allogeneic stem cell transplantation); 3. The expected survival period should be >3 months.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Uncontrolled positive infection, hepatitis B or hepatitis C positive; 3. Use systemic steroids; 4. Previously received any other cell modification treatment.

Design outcomes

Primary

MeasureTime frame
Tumor reaction;Patient survival;—

Secondary

MeasureTime frame
CD19-CART cells survive and expand in vivo;—

Countries

China

Contacts

Public ContactYingmin Liang
liangym@fmmu.edu.cn+86 13891966009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026